title: Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant.
abstract: Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.
authors: Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA.
authors: Michael
authors: M
authors: Cecchini
authors: Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA.
authors: Mario
authors: M
authors: Sznol
authors: Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA.
authors: Stuart
authors: S
authors: Seropian
keywords: Allogeneic transplant; CTLA-4 antigen; Graft vs host disease; Immunotherapy; Interleukin-2; Ipilimumab; Melanoma; Programmed cell death 1 receptor and immune-related adverse events